Tenecteplase compares favorably to alteplase in new comparison of FDA-approved stroke drugs

Tenecteplase, a new drug that just gained U.S. Food and Drug Administration (FDA) approval for treating acute ischemic stroke (AIS) in adults, is associated with short-term safety and effectiveness outcomes that are similar to alteplase, according to new findings published in JAMA Network Open.[1]

Tenecteplase is a clot-dissolving drug sold and marketed by Genentech under the brand name TNKase. It is only the second drug of its kind to gain FDA approval. The first was alteplase, which Genentech sells and markets under the brand name Activase.